Antineoplastic Agents, Immunological

"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000074322
MeSH Number(s)	D27.505.954.248.384
Concept/Terms	Antineoplastic Agents, Immunological Antineoplastic Agents, Immunological Immunological Antineoplastic Agents Antineoplastics, Monoclonal Antibodies Antineoplastics, Monoclonal Antibodies Antibodies Antineoplastics, Monoclonal Monoclonal Antibodies Antineoplastics Monoclonal Antibodies, Antineoplastic Antineoplastic Monoclonal Antibodies Antineoplastic MAbs Antineoplastics, Monoclonal Antibody Monoclonal Antibody Antineoplastics MAbs, Antineoplastic

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Immunological [D27.505.954.248.384]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Immunological".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.

Bar chart showing 21 publications over 6 distinct years, with a maximum of 5 publications in 2019 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2016	0	2	2
2017	2	0	2
2018	2	2	4
2019	3	2	5
2020	5	0	5
2021	1	2	3

Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.

Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, Lentsch EJ, Hornig JD, Skoner J, Stalcup S, Spampinato MV, Garrett-Mayer E, O'Quinn EC, Timmers CD, Romeo MJ, Wrangle JM, Young MRI, Rubinstein MP, Day TA, Lo RS, Paulos CM, Neskey DM. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.

View in: PubMed
Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100411.

View in: PubMed
Bennett CL, Focosi D, Socal MP, Bian JC, Nabhan C, Hrushesky WJ, Bennett AC, Schoen MW, Berger JR, Armitage JO. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021 Aug; 8(8):e593-e604.

View in: PubMed
Bennett CL, Schoen MW, Hoque S, Witherspoon BJ, Aboulafia DM, Hwang CS, Ray P, Yarnold PR, Chen BK, Schooley B, Taylor MA, Wyatt MD, Hrushesky WJ, Yang YT. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.

View in: PubMed
Yazdani M, Antonucci M, Spampinato MV. Brain Lesion in the Setting of Chronic Rituximab Treatment. JAMA Oncol. 2020 07 01; 6(7):1093-1094.

View in: PubMed
Sun F, Guo ZS, Gregory AD, Shapiro SD, Xiao G, Qu Z. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. J Immunother Cancer. 2020 05; 8(1).

View in: PubMed
Watanabe Y, Yamaguchi Y, Takamura N, Takahashi Y, Aihara M. Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab. Eur J Cancer. 2020 05; 131:1-4.

View in: PubMed
Xiong Y, Neskey DM, Horton JD, Paulos CM, Knochelmann HM, Armeson KE, Young MRI. Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma. BMC Cancer. 2020 Mar 17; 20(1):229.

View in: PubMed
Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). J Immunother Cancer. 2019 11 29; 7(1):332.

View in: PubMed
Sun F, Li L, Yan P, Zhou J, Shapiro SD, Xiao G, Qu Z. Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance. Nat Commun. 2019 11 22; 10(1):5324.

View in: PubMed

People

Explore

Similar Concepts

Top Journals